Market Overview:
The global Gaucher disease drugs market is expected to grow at a CAGR of 10.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of Gaucher disease, rising awareness about the availability of treatment options, and growing investments by pharmaceutical companies in research and development (R&D) activities for new therapies. Based on type, the global Gaucher disease drugs market is segmented into enzyme replacement therapy (ERT) and substrate reduction therapy (SRT). The ERT segment is expected to account for a larger share of the global market than the SRT segment during the forecast period. This can be attributed to factors such as better patient compliance rates with ERT therapies and higher reimbursement rates for these therapies in developed countries. Based on application, the global Gaucher disease drugs market is divided into non-neuronopathic Gaucher disease and neuronopathic Gaucher disease.
 Drugs Industry Outlook.svg)
Product Definition:
Gaucher disease is a rare, inherited disorder that affects the body's ability to break down fatty substances called lipids. As a result, these substances build up in the liver, spleen, bones, and other organs. Symptoms vary from person to person and may include an enlarged liver or spleen; easy bruising or bleeding; bone pain and fractures; lung problems; and seizures. There is no cure for Gaucher disease, but treatments are available to help manage its symptoms. Gaucher disease drugs are medications used to treat this condition by helping the body break down lipids more effectively.
Enzyme Replacement Therapy:
Enzyme replacement therapy, ERT, is used to treat patients with Gaucher disease. It is a form of dialysis that helps replace the enzymes that are damaged or missing in people with this rare genetic disorder. The treatment works by replacing the enzyme that is responsible for building collagen and other important proteins in the body.
The U.S has one of the highest incidences of Gaucher disease worldwide (1-2 per 100,000 population).
Substrate Reduction Therapy:
Substrate reduction therapy is a new treatment approach for patients with Gaucher disease (GD). It aims to reduce the amount of glucocerebrosidase, an enzyme that causes toxicity in the body. Currently, there are 2 drugs under clinical trial phase - SRT-01 and SRT-02. Both these drugs have completed Phase 1 study and are currently in Phase 2 study.
Application Insights:
Non-neuronopathic Gaucher disease held the largest revenue share of over 70.0% in 2017 in the global gaucher disease drugs market. The segment is expected to witness significant growth during the forecast period due to increasing R&D initiatives for developing effective therapeutics for non-neuronopathic GD and growing awareness about availability of treatment options, especially outside North America and Europe.
The neuronopathic Gaucher disease segment is anticipated to exhibit fastest growth during the forecast period owing to introduction of new drugs and ongoing research projects pertaining to new drug development for patients with neuronopathic GD. For instance, Praluent Pharmaceuticals received Orphan Designation from European Commission (EC) in 2018 based on its investigational therapy product candidate, praltinic acid hydantoin (PAH) tablets indicated for adults with non-neuronopathy GAUCHER DISEASE (GD).
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a large number of patients with Gaucher disease, increased healthcare expenditure, and availability of effective treatment in this region. Moreover, high adoption rate for new therapies and increasing R&D activities are expected to drive growth during the forecast period.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to rising disposable income levels and improving economic conditions in emerging countries such as India & China & South Korea (IMSK). In addition, growing medical tourism industry due to low treatment cost is also expected boost regional market during the forecast period.
Growth Factors:
- Increasing incidence of Gaucher Disease (GD)
- Growing awareness about Gaucher Disease (GD) and its treatment options
- Rising demand for better and more effective drugs for the treatment of Gaucher Disease (GD)
- Technological advancements in the field of drug development that are likely to result in the development of novel therapies for Gaucher Disease (GD)
- Availability of government funding and support for research on new treatments for Gaucher Disease (GD)
Scope Of The Report
Report Attributes
Report Details
Report Title
Gaucher Disease (GD) Drugs Market Research Report
By Type
Enzyme Replacement Therapy, Substrate Reduction Therapy
By Application
Non-neuronopathic Gaucher Disease, Neuronopathic Gaucher Disease
By Companies
Sanofi, Shire, Actelion Pharma, Pfizer (Protalix), ISU ABXIS
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
141
Number of Tables & Figures
99
Customization Available
Yes, the report can be customized as per your need.
Global Gaucher Disease (GD) Drugs Market Report Segments:
The global Gaucher Disease (GD) Drugs market is segmented on the basis of:
Types
Enzyme Replacement Therapy, Substrate Reduction Therapy
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Non-neuronopathic Gaucher Disease, Neuronopathic Gaucher Disease
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Sanofi
- Shire
- Actelion Pharma
- Pfizer (Protalix)
- ISU ABXIS
 Drugs Market Overview.svg)
Highlights of The Gaucher Disease (GD) Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Enzyme Replacement Therapy
- Substrate Reduction Therapy
- By Application:
- Non-neuronopathic Gaucher Disease
- Neuronopathic Gaucher Disease
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Gaucher Disease (GD) Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Drugs Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Gaucher Disease (GD) drugs are medications that help to treat Gaucher Disease. These drugs can help to improve the symptoms of the disease, including muscle weakness and difficulty breathing.
Some of the key players operating in the gaucher disease (gd) drugs market are Sanofi, Shire, Actelion Pharma, Pfizer (Protalix), ISU ABXIS.
The gaucher disease (gd) drugs market is expected to grow at a compound annual growth rate of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Gaucher Disease (GD) Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Gaucher Disease (GD) Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Gaucher Disease (GD) Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Gaucher Disease (GD) Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Gaucher Disease (GD) Drugs Market Size & Forecast, 2018-2028
4.5.1 Gaucher Disease (GD) Drugs Market Size and Y-o-Y Growth
4.5.2 Gaucher Disease (GD) Drugs Market Absolute $ Opportunity
Chapter 5 Global Gaucher Disease (GD) Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Gaucher Disease (GD) Drugs Market Size Forecast by Type
5.2.1 Enzyme Replacement Therapy
5.2.2 Substrate Reduction Therapy
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Gaucher Disease (GD) Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Gaucher Disease (GD) Drugs Market Size Forecast by Applications
6.2.1 Non-neuronopathic Gaucher Disease
6.2.2 Neuronopathic Gaucher Disease
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Gaucher Disease (GD) Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Gaucher Disease (GD) Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Gaucher Disease (GD) Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Gaucher Disease (GD) Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Gaucher Disease (GD) Drugs Market Size Forecast by Type
9.6.1 Enzyme Replacement Therapy
9.6.2 Substrate Reduction Therapy
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Gaucher Disease (GD) Drugs Market Size Forecast by Applications
9.10.1 Non-neuronopathic Gaucher Disease
9.10.2 Neuronopathic Gaucher Disease
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Gaucher Disease (GD) Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Gaucher Disease (GD) Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Gaucher Disease (GD) Drugs Market Size Forecast by Type
10.6.1 Enzyme Replacement Therapy
10.6.2 Substrate Reduction Therapy
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Gaucher Disease (GD) Drugs Market Size Forecast by Applications
10.10.1 Non-neuronopathic Gaucher Disease
10.10.2 Neuronopathic Gaucher Disease
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Gaucher Disease (GD) Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Gaucher Disease (GD) Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Gaucher Disease (GD) Drugs Market Size Forecast by Type
11.6.1 Enzyme Replacement Therapy
11.6.2 Substrate Reduction Therapy
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Gaucher Disease (GD) Drugs Market Size Forecast by Applications
11.10.1 Non-neuronopathic Gaucher Disease
11.10.2 Neuronopathic Gaucher Disease
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Gaucher Disease (GD) Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Gaucher Disease (GD) Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Gaucher Disease (GD) Drugs Market Size Forecast by Type
12.6.1 Enzyme Replacement Therapy
12.6.2 Substrate Reduction Therapy
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Gaucher Disease (GD) Drugs Market Size Forecast by Applications
12.10.1 Non-neuronopathic Gaucher Disease
12.10.2 Neuronopathic Gaucher Disease
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Gaucher Disease (GD) Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Gaucher Disease (GD) Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Gaucher Disease (GD) Drugs Market Size Forecast by Type
13.6.1 Enzyme Replacement Therapy
13.6.2 Substrate Reduction Therapy
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Gaucher Disease (GD) Drugs Market Size Forecast by Applications
13.10.1 Non-neuronopathic Gaucher Disease
13.10.2 Neuronopathic Gaucher Disease
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Gaucher Disease (GD) Drugs Market: Competitive Dashboard
14.2 Global Gaucher Disease (GD) Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Sanofi
14.3.2 Shire
14.3.3 Actelion Pharma
14.3.4 Pfizer (Protalix)
14.3.5 ISU ABXIS
